OpenAI is one of the most valuable private companies in the world, and retail investors keep running into the same wall when they try to own a piece of it. The maker of ChatGPT closed the largest private funding round in history on March 31, 2026, lifting its post-money valuation to $852 billion and leapfrogging SpaceX for the top spot in private markets. There is no OpenAI ticker, no prospectus, and no way to place a standard buy order at your brokerage.

That has not stopped individual investors from finding creative paths to exposure, and a handful of those paths have genuinely opened up over the last six months. Here is what actually works, what only partially works, and where the risks hide.

Why OpenAI Shares Don't Trade On The Nasdaq

OpenAI's corporate structure is deliberately unusual, and that is the root of the access problem. The OpenAI Foundation, a nonprofit, holds a controlling equity stake in OpenAI Group PBC, the for-profit public benefit corporation that runs ChatGPT and the enterprise business. Any transfer of shares in the PBC requires board approval, and direct investment in OpenAI or the venture funds backing it is legally restricted to accredited investors, who must meet income or net-worth thresholds set by the Securities and Exchange Commission.

OpenAI is also in no rush to list. CEO Sam Altman has said he is "zero percent excited" about running a public company, and while he has reportedly pushed internally for a Q4 2026 IPO, CFO Sarah Friar believes a 2027 listing is more realistic given the organizational work required. Until then, retail investors have to go sideways.

The Microsoft Workaround

The cleanest indirect route runs through Microsoft (NASDAQ:MSFT). Microsoft holds roughly 27% of OpenAI Group PBC on an as-converted diluted basis, an investment valued at approximately $135 billion as of the late-2025 recapitalization. Microsoft also receives 20% of OpenAI's revenue under an agreement that runs through 2032.

The appeal is obvious. You buy Microsoft on any brokerage, pay no special fees, and get proportional upside if OpenAI grows. The limitation is just as obvious. At Microsoft's market capitalization, the OpenAI stake represents roughly 8% of the total, which means OpenAI performance gets diluted against Azure, Office, LinkedIn, gaming, and everything else Satya Nadella runs. If your thesis is "OpenAI specifically," Microsoft gives you a watered-down version. If your thesis is "the AI buildout broadly," it is arguably a better bet than a pure-play.

ARK Invest's Two Doors Into OpenAI

Cathie Wood's firm opened two different entry points for retail investors in 2026. The primary vehicle is the ARK Venture Fund (ARKVX), a closed-end interval fund that has held OpenAI since 2023 and carries it as roughly 11% of the portfolio, second only to SpaceX at 17%.

ARKVX has real drawbacks that investors should understand before subscribing. It is an interval fund, so shares can only be redeemed during quarterly liquidity windows, and even then ARK can limit the buyback to a set percentage of net assets. The gross expense ratio is 3.49%, with a current net ratio of 2.90% after contractual waivers. Retail access is limited to SoFi and Titan Global Capital Management, while Charles Schwab and Fidelity offer it through registered investment advisors.

For investors who want daily liquidity, ARK's more accessible move came on March 31, 2026, when the firm added a combined $240 million of OpenAI shares to three of its flagship ETFs, the ARK Innovation ETF (BATS:ARKK), the ARK Next Generation Internet ETF (BATS:ARKW), and the ARK Fintech Innovation ETF (BATS:ARKF). Each fund received roughly 3% OpenAI weighting. The trade-off is obvious. You get daily tradability and much lower expense ratios, but only modest OpenAI exposure buried inside a portfolio of dozens of other holdings.

The Fundrise Innovation Fund And Its Extreme Premium

The Fundrise Innovation Fund (NYSE:VCX) went public on March 19, 2026, marketed as "the public ticker for private tech." It is a closed-end fund holding Anthropic at roughly 20.7%, Databricks at 17.7%, OpenAI at 9.9%, Anduril at 6.9%, and SpaceX at 5%, among other names.

VCX has delivered spectacular early gains for holders and a spectacular warning for newcomers. The fund surged more than 590% in its first three trading days, with intraday halts triggered by volatility. At one point it traded more than 1,300% above its net asset value. That extreme premium reflects locked-up supply, because pre-listing shareholders cannot sell for six months after the debut, which has kept the tradable float extremely thin.

Paying a premium of that magnitude means you are not buying OpenAI at an $852 billion valuation, you are buying it at multiples of that implied value. A disciplined approach is to wait for the six-month lockup to roll off, watch the premium compress, and consider entry only when the market price sits closer to the underlying net asset value.

Secondary Markets For Accredited Investors

If you qualify as an accredited investor, private share platforms like Hiive, Forge Global, and EquityZen post direct secondary listings of OpenAI stock from employees and early investors. Minimums typically start around $10,000 to $25,000 per trade, and pricing is negotiated between buyer and seller. OpenAI's own recent tenders closed at an implied $500 billion valuation in October 2025 and an $852 billion valuation in March 2026, so secondary market spreads tend to reference those benchmarks.

The practical issues are illiquidity, since you cannot exit on a whim, company approval requirements for most transfers, and the accreditation gate itself, which excludes most retail investors by design.

What To Weigh Before You Commit Capital

Three questions deserve honest answers before you buy any of these vehicles.

First, is the premium worth it? VCX has traded at an extreme markup, and even ARKVX carries meaningful fees. Microsoft, by contrast, trades at a normal forward multiple with OpenAI thrown in. Know what you are paying for the exposure before you click buy.

Second, do you need liquidity? ARKVX only redeems quarterly, with caps. Secondary platforms can tie up capital for years. ETFs and MSFT give you true daily liquidity. The right choice depends on whether this is a satellite position or a meaningful allocation.

Third, what happens if OpenAI never goes public, or lists at a markdown? OpenAI is projected to lose roughly $14 billion in 2026, and its CFO has publicly pushed back on aggressive spending plans. Competition from Anthropic, Google's Gemini, and well-funded Chinese models is intensifying. A 2027 or later listing is plausible, and a haircut to the $852 billion benchmark is not impossible.

OpenAI exposure is finally within reach for ordinary investors, but the right vehicle depends on conviction level, time horizon, and tolerance for illiquidity. The real mistake to avoid is buying at a price that's much higher than the actual intrinsic value of the asset just because you're afraid to miss out. It is better to wait for a reasonable price than to overpay for a “hot” investment, as a high purchase price directly cripples your potential to make money in the long term.

Image credit: Author

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.